Nasal glucagon: A new hope for severe hypoglycemia in type 1 diabetes
Until now, injectable glucagon was the only available treatment used in the management of severe hypoglycemia wherein glucagon had to be prepared in several steps before administration. This method of delivery of injectable glucagon being cumbersome and unappealing for wide majority of the patients had led to a search for an alternative route of drug delivery. nasal glucagon (NG) now serves an efficient, safe, easy-to-administer, and a favorable substitute to glucagon injections. This ready to use device stand in clear contrast to overcome the limitations associated with the currently available glucagon preparations has emerged a key advancement in the management of severe hypoglycemia in adolescents and children with type 1 diabetes. NG is now being developed and studied in other countries as well to meet the unmet need for an easy and convenient glucagon administration. This review covers the basic information of nasal glucagon, trials on nasal glucagon in children and adults and its potential uses, limitations, and future scope in practice.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Nasal glucagon: A new hope for severe hypoglycemia in type 1 diabetes ; volume:04 ; number:01 ; year:2021 ; pages:13-18
Journal of diabetes & endocrine practice ; 04, Heft 01 (2021), 13-18
- Beteiligte Personen und Organisationen
-
Heba, Salva
Parveen, Uzma
Khanum, Sara
Gulnaaz, Maaria
Tabassum, Maimuna
Safiyya, Syeda
- DOI
-
10.4103/jdep.jdep_6_20
- URN
-
urn:nbn:de:101:1-2022101004204541156043
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heba, Salva
- Parveen, Uzma
- Khanum, Sara
- Gulnaaz, Maaria
- Tabassum, Maimuna
- Safiyya, Syeda
Ähnliche Objekte (12)
Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
Tigecycline-induced sustained severe hypoglycemia: a case report
Severe hypoglycemia reduces the shivering threshold in rabbits
Neurodevelopmental outcomes after moderate to severe neonatal hypoglycemia
Severe hypoglycemia with trastuzumab: An unseen adverse event
Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
Dasiglucagon in severe hypoglycemia: a profile of its use
Regulation of IGF-1 bioactivity by dietary hormones, impact of glucagon and insulin-induced hypoglycemia
A case of hypothalamic hypopituitarism accompanied by recurrent severe hypoglycemia
Identifying people at risk for severe hypoglycemia by CGM in a sample of people with reduced hypoglycemia awareness
A novel nasal powder formulation of glucagon: toxicology studies in animal models
Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
Tigecycline-induced sustained severe hypoglycemia: a case report
Severe hypoglycemia reduces the shivering threshold in rabbits
Neurodevelopmental outcomes after moderate to severe neonatal hypoglycemia
Severe hypoglycemia with trastuzumab: An unseen adverse event
Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
Dasiglucagon in severe hypoglycemia: a profile of its use
Regulation of IGF-1 bioactivity by dietary hormones, impact of glucagon and insulin-induced hypoglycemia
A case of hypothalamic hypopituitarism accompanied by recurrent severe hypoglycemia
Identifying people at risk for severe hypoglycemia by CGM in a sample of people with reduced hypoglycemia awareness
A novel nasal powder formulation of glucagon: toxicology studies in animal models
Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
Tigecycline-induced sustained severe hypoglycemia: a case report
Severe hypoglycemia reduces the shivering threshold in rabbits
Neurodevelopmental outcomes after moderate to severe neonatal hypoglycemia
Severe hypoglycemia with trastuzumab: An unseen adverse event
Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons
Dasiglucagon in severe hypoglycemia: a profile of its use
Regulation of IGF-1 bioactivity by dietary hormones, impact of glucagon and insulin-induced hypoglycemia
A case of hypothalamic hypopituitarism accompanied by recurrent severe hypoglycemia
Identifying people at risk for severe hypoglycemia by CGM in a sample of people with reduced hypoglycemia awareness